Gritstone Bio Inc   (GRTS)
Other Ticker:  

Gritstone Bio Inc 's



GRTS Sales vs. its Competitors Q3 2023

Revenue Growth Comparisons

Net Income Comparison

<<  GRTS Stock Performance Comparisons

*Market share is calculated based on total revenue.

  News about Gritstone Bio Inc Contracts

Gritstone Bio Announces Delay in Phase 2b COVID-19 Clinical Trial for Optimal Vaccine Development

EMERYVILLE, Calif., Feb. 12, 2024 - Gritstone bio, Inc. (Nasdaq: GRTS), a pioneering biotechnology company focused on developing the world's most powerful vaccines, has shared an important update on its comparative Phase 2b COVID-19 clinical trial. The company is now preparing to launch the much-anticipated trial in the Fall of 2024, rather than the previously scheduled 1Q24. This delay is necessary to incorporate fully Good Manufacturing Practice (GMP)-grade raw materials in the vaccine formulation, enabling enhanced regulatory compliance and optimizing the trial's potential.The decision to delay the Phase 2b trial stems from Gritstone Bio's commitment to ensuring the highest quality and efficacy of its nex...

Who are Gritstone Bio Inc 's Competitors?


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com